BRIDGEBIO PHARMA INCORPORATED (BBIO)

Calendar & Research Financial Calendar Earnings Calendar & Reports Analyst Ratings Fund Letters Archive Transcripts Search Stock Market Holidays ... On June 30, 2026, BlackRock, Inc. (Trades, Portfolio) executed a significant reduction in its position in BridgeBio Pharma Inc BBIO, selling 4,473,995 …

The company missed first-quarter ... 9%. The earnings miss raised questions about spending discipline as BridgeBio prepares to launch three additional products—BBP-418 for a muscular dystrophy, encaleret, and infigratinib for skeletal disorders—over the next 12 months. Thursday’s results will test w…

BridgeBio Pharma stock has delivered a 149.6% return over the past three years, yet its valuation checks lean expensive and suggest the recent strength may already price in a lot of good news. With the company now highlighting a potential blockbuster opportunity around its encaleret program, ...

BridgeBio Pharma (BBIO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estim…

BridgeBio Pharma (NASDAQ:BBIO) will be releasing its Q2 2026 earnings after the market closes on Tuesday, August 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-8-4-bridgebio-pharma-inc-stock/)